Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Vanessa Arciero"'
Autor:
Wei Fang Dai, Vanessa Arciero, Erica Craig, Brent Fraser, Jessica Arias, Darryl Boehm, Nevzeta Bosnic, Patricia Caetano, Carole Chambers, Barry Jones, Elena Lungu, Gunita Mitera, Tanya Potashnik, Anthony Reiman, Trevor Ritcher, Jaclyn M. Beca, Avram Denburg, Rebecca E. Mercer, Ambica Parmar, Mina Tadrous, Pam Takhar, Kelvin K. W. Chan, on behalf of the CanREValue Collaboration Reassessment and Uptake Working Group
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 4174-4183 (2021)
The Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) Collaboration was established to develop a framework for generating and using real-world evidence (RWE) to inform the reassessment of cancer drugs following initial health techno
Externí odkaz:
https://doaj.org/article/9c275cad03714dd78f5a9502b73ba44d
Autor:
Ambica Parmar, Vanessa Arciero, Erica Craig, Anthony Reiman, Darryl Boehm, Rebecca E Mercer, Kelvin K. W. Chan, Avram Denburg, Patricia Caetano, Jessica Arias, Barry Jones, Tanya M Potashnik, Pam Takhar, Wei Fang Dai, Elena R Lungu, Carole R Chambers, Jaclyn Beca, Mina Tadrous, Gunita Mitera, Nevzeta Bosnic, Trevor Ritcher, Brent Fraser
Publikováno v:
Current Oncology
Current Oncology, Vol 28, Iss 354, Pp 4174-4183 (2021)
Current Oncology, Vol 28, Iss 354, Pp 4174-4183 (2021)
The Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) Collaboration was established to develop a framework for generating and using real-world evidence (RWE) to inform the reassessment of cancer drugs following initial health techno
Autor:
Vanessa, Arciero, Erica, McDonald, Vivian, Nguyen, Ronak, Saluja, Michael, Raphael, Ambica, Parmar, Kelvin K W, Chan
Publikováno v:
Journal of Cancer Research and Clinical Oncology.
The National Institutes of Health's policy for the inclusion of females in clinical research was a pivotal step towards the consideration of sex as a biological variable, which is of particular importance in oncology, given differential incidence and
Autor:
Vanessa Arciero, Jin Luo, Ambica Parmar, Wei Fang Dai, Jaclyn M Beca, Michael J Raphael, Wanrudee Isaranuwatchai, Steven Habbous, Mina Tadrous, Craig C Earle, Jim J Biagi, Nicole Mittmann, Jessica Arias, Scott Gavura, Kelvin K W Chan
Publikováno v:
JNCI Cancer Spectrum. 6
Background There are no randomized control trials (RCTs) comparing gemcitabine and nab-paclitaxel (Gem-Nab) and fluorouracil, folinic acid, irinotecan, oxaliplatin (FOLFIRINOX) for advanced pancreatic cancer (APC). Although it is well known that RCT-
Publikováno v:
Journal of Clinical Oncology. 40:17-17
17 Background: Randomized controlled trials (RCTs) demonstrate large survival benefits with anti-PD-1 checkpoint inhibitors compared to anti-CTLA4 therapy for advanced melanoma. However, it remains unclear if patients in routine practice derive a sim
Autor:
Vanessa Arciero, Jin Luo, Ambika Parmar, Wei Fang Dai, Jaclyn M. Beca, Michael J. Raphael, Wanrudee Isaranuwatchai, Steven Habbous, Mina Tadrous, Craig Earle, Jim Biagi, Nicole Mittmann, Jessica Arias, Scott Gavura, Kelvin K. Chan
Publikováno v:
Journal of Clinical Oncology. 40:529-529
529 Background: Currently, there are no direct randomized control trials (RCTs) comparing gemcitabine and nab-paclitaxel (Gem-Nab) and FOLFIRINOX for advanced pancreatic cancer (APC). Thus, previous model-based cost-effectiveness analyses were based
Autor:
Sierra Cheng, Mahin Qureshi, Kelvin K. W. Chan, Vanessa Arciero, Erica McDonald, Matthew C. Cheung
Publikováno v:
Blood. 128:3578-3578
Introduction The cost of cancer care is rising to unsustainable levels, predominantly driven by an increase in expenditures for novel therapies. In the era of biologic therapies, these excessive costs are disproportionately borne by patients with hem